Vaccine manufacturing facilities have had to rapidly ramp up their capabilities to produce RNA vaccines. Credit: Olivier Maire/EPA-EFE/Shutterstock
It was a Friday afternoon in March 2013 when Andy Geall got the call. Three people in China had just become infected with a newstrain of avian influenza. The global head of vaccines research at Novartis, Rino Rappuoli, wanted to know whether Geall and hiscolleagues were ready to put their new vaccine technology to the test.
NEWS FEATURE ·
12 JANUARY 2021
How COVID unlocked the power of RNA vaccines
The technology could revolutionize efforts to immunize against HIV, malaria, influenza and more.
Elie Dolgin
nature
news feature
article
View All Nature Research Journals
Search
Login
Content
Journal Info
Publish
Sign Up For Alerts
RSS Feed
A year earlier, Geall’s team at Novartis’s US research hub in Cambridge, Massachusetts, had packaged strings of RNA nucleotidesinside of small fat droplets, known as lipid nanoparticles (LNPs), and used them to successfully vaccinate rats against a respiratoryvirus
. Could they now do the same for the novel flu strain? And could they do it as fast as possible?
As Geall, head of the RNA group, recalls: “I said, ‘Yeah, sure. Just send us the sequence.’” By Monday, the team had begunsynthesizing the RNA. By Wednesday, they were assembling the vaccine. By the weekend, they were testing it in cells — a weeklater, in mice
.
The development happened at a breakneck speed
. The Novartis team had achieved in one month what typically took a year ormore.
But at the time, the ability to manufacture clinical-grade RNA was limited. Geall and hiscolleagues would never find out whether this vaccine, and several others that they developed,would work in people. In 2015, Novartis sold its vaccines business.
Five years and one global pandemic later, RNA vaccines are proving their worth. Last month, twoRNA vaccine candidates — one from US pharmaceutical giant Pfizer and BioNTech in Mainz,Germany, and another from Moderna in Cambridge, Massachusetts — won emergency approvalfrom regulators in several countries to fight COVID-19.
The era of RNA vaccines has arrived — and dozens of companies are getting in the game. “All ofthe major pharmas are, in one way or the other, now testing out the technology,” says JeffreyUlmer, former head of preclinical research and development at GlaxoSmithKline’s vaccinedivision in Rockville, Maryland, and before that a member of Geall’s team at Novartis.
The idea of using RNA in vaccines has been around for nearly three decades. More streamlined than conventional approaches, thegenetic technology allows researchers to fast-track many stages of vaccine research and development. The intense interest nowcould lead to solutions for particularly recalcitrant diseases, such as tuberculosis, HIV and malaria. And the speed at which theycan be made could improve seasonal-flu vaccines.
But future applications of the technology will run up against some challenges. The raw materials are expensive. Side effects can betroubling. And distribution currently requires a costly cold chain — the Pfizer–BioNTech COVID-19 vaccine, for example, must bestored at −70 °C. The urgency of COVID-19 is likely to speed up progress on some of those problems, but many companies mightabandon the strategy once the current crisis subsides. The question remains: where will it end up?
“The RNA technology has proved itself, but it’s not done yet,” says Philip Dormitzer, head of viral vaccines research at Pfizer, and aformer colleague of Geall’s at Novartis. “And now that we’ve seen it work for COVID-19, it’s tempting to want to do more.”
Small particles, big advance
Vaccines teach the body to recognize and destroy disease-causing agents. Typically, weakened pathogens or fragments of theproteins or sugars on their surfaces, known as antigens, are injected to train the immune system to recognize an invader. But RNAvaccines carry only the directions for producing these invaders’ proteins. The aim is that they can slip into a person’s cells and getthem to produce the antigens, essentially turning the body into its own inoculation factory.
The idea for RNA-based vaccination dates back to the 1990s, when researchers in France (at what is now the drug firm SanofiPasteur) first used RNA encoding an influenza antigen in mice
. It produced a response, but the lipid delivery system that the teamused proved too toxic to use in people. It would take another decade before companies looking at RNA-interference therapeutics
1
2
3
COVID-19 vaccines poised forlaunch, but impact on pandemicunclear
RELATED
4
— which rely on RNA’s ability to selectively block the production of specific proteins — discovered the LNP technologies that wouldmake today’s COVID-19 vaccines possible.
Vaccine manufacturing facilities have had to ramp up their capabilities to produce RNA vaccines.
Credit: Robin van Lonkhuijsen/ANP/AFP/Getty
“Finally, there was the breakthrough,” says Nick Jackson, head of programmes and innovative technologies at the Coalition forEpidemic Preparedness Innovations in Oslo, a global partnership to accelerate vaccine development. “That was really thewatershed that allowed the application of messenger RNA to a whole range of different disease indications.”
In 2012, around the time that Geall and his colleagues described
the first LNP-encapsulated RNA vaccine, the US DefenseAdvanced Research Projects Agency (DARPA) began funding groups at Novartis, Pfizer, AstraZeneca, Sanofi Pasteur and elsewhereto work on RNA-encoded vaccines and therapeutics. None of the big-name firms stuck with the technology, however. “They werereticent about taking on any risk with a new regulatory pathway for vaccines, even though the data looked good,” says DanWattendorf, a former programme manager at DARPA.
But two smaller firms with ties to the DARPA programme continued to work on the technology. One was CureVac in Tübingen,Germany, which began human testing of a rabies vaccine in 2013
. CureVac also has a COVID-19 vaccine in late-stage testing.
The other was Moderna, which built on work funded by DARPA to eventually bring an RNA-based vaccine for a new strain of avianinfluenza into clinical testing in late 2015. It elicited strong enough immune responses
that the company moved ahead withhuman trials of RNA vaccines for cytomegalovirus (a common cause of birth defects), two mosquito-borne viruses (chikungunyaand Zika) and three viral causes of respiratory illness in children.
GlaxoSmithKline, which had acquired most of Novartis’s vaccine assets, also began evaluating an RNA-based rabies vaccine in2019.
1
5
6
That was the full extent of clinical development for RNA vaccines at the beginning of 2020: only adozen candidates had gone into people; four were swiftly abandoned after initial testing; andonly one, for cytomegalovirus, had progressed to a larger, follow-on study.
Then came the coronavirus — and with it, “there’s been this enormous spotlight”, says KristieBloom, a gene-therapy researcher at the University of the Witwatersrand in Johannesburg, SouthAfrica. In the past ten months alone, at least six RNA-based COVID-19 vaccines have enteredhuman testing. Several more are nearing the clinic.
Need for speed
RNA vaccines seem built for speed. From the genetic sequence of a pathogen, researchers canquickly pull out a potential antigen-encoding segment, insert that sequence in a DNA template and then synthesize thecorresponding RNA before packaging the vaccine for delivery into the body.
Moderna, for example, managed this within 4 days of receiving the SARS-CoV-2 genome sequence. It focused on the virus’s spikeprotein, a surface protein used to enter cells. Collaborating with the US National Institutes of Health, the company then ran proof-of-concept experiments in mice before kicking off first-in-human testing in a span of just two months.
Any vaccine, in theory, could be created in the same way. “It truly is a platform in that sense,” says John Shiver, head of vaccineresearch and development at Sanofi Pasteur. With RNA, “you don’t have to recreate the entire process”.
Classical approaches to vaccine creation, by contrast, require bespoke, expensive and time-consuming steps for every candidate.These inefficiencies help to explain why health authorities must choose which strains to put into each year’s seasonal-flu vaccinemonths ahead of flu season. Those choices often miss the mark, and there is no time to go back and test an alternative. As a result,flu vaccines are rarely more than 60% effective.
With RNA, however, vaccine makers could more quickly pivot to an effective selection ofantigens. “You could theoretically move very fast to adjust sequence and address that — almoston the fly,” says Ron Renaud, chief executive of Translate Bio, an RNA-focused company inLexington, Massachusetts, that is working with Sanofi Pasteur on RNA-based vaccines forinfluenza, COVID-19 and several other viral and bacterial pathogens.
Thanks to their plug-and-play functionality, RNA vaccines could aid basic research. JustinRichner, a vaccinologist at the University of Illinois College of Medicine in Chicago, is developinga RNA-based dengue vaccine in his own laboratory. Richner and his colleagues routinely chopand change the gene sequence encoding the envelope protein that the dengue virus uses tolaunch its attack on human cells. By iterating their design, the researchers have tested around 15vaccine candidates in mice.
“It’s really easy to manipulate the coding sequence of the vaccine to try new hypotheses and strategies that may make for bettervaccines,” says Richner.
Other treasures
Advances in the technology are now helping researchers to close in on some of the holy grails of vaccine development — such as auniversal flu shot that would work against any strain of the virus without being redesigned each year. Others are eyeing jabsagainst HIV and other top killers in lower-income countries. Such vaccines have eluded scientists often because of the way that
Could new COVID variantsundermine vaccines? Labsscramble to find out
RELATED
The lightning-fast quest forCOVID vaccines — and what itmeans for other diseases
RELATED
pathogens systematically alter their surface proteins to evade immune recognition. Some infectious agents, such as malaria, alsohave elaborate life cycles that further complicate the process of picking antigens.
RNA vaccines could include instructions for multiple antigens, either strung together in a single strand, or with several RNAspackaged together in a single nanoparticle.
Norbert Pardi, a vaccine scientist at the University of Pennsylvania Perelman School of Medicine in Philadelphia, took the latterapproach for his experimental flu vaccine. Made of four RNA strands, each encoding a different influenza protein, the multiplexvaccine successfully protected mice from infection with one particular subtype of influenza virus
.
Now, Pardi and his collaborators at the Icahn School of Medicine at Mount Sinai in New York City hope to repeat the exercise forthe other 2 main viral subtypes before putting everything together into a 12-strand flu shot that could supplant the need forannual vaccination. “If you hit the virus at multiple points,” Pardi says, “you can induce broadly protective immune responses.”
Stability and safety
Despite its many potential advantages, today’s RNA-vaccine technology leaves room for improvement. “This technology is stillsuper early,” says Robin Shattock, an immunologist at Imperial College London, “and we’re going to see multiple generations anditerations over the coming years, I suspect.”
First, there’s the issue of cold storage. Both the Pfizer–BioNTech and Moderna vaccines require cold temperatures to maintain theintegrity of their RNA.
But at least two companies claim to have COVID-19 RNA vaccines that are stable for months atwarmer temperatures.
CureVac, which uses the same LNPs as Pfizer–BioNTech, folds its RNA into compact 3Dstructures, which allows for storage at refrigerated temperatures for months, says chieftechnology officer Mariola Fotin-Mleczek. And Suzhou Abogen Biosciences, a Chinese companywith an RNA vaccine for COVID-19 now in early human testing, has focused on LNP quality andpurity to create a product that reportedly maintains its potency for up to one week at roomtemperature
.
There’s another challenge: so far, RNA vaccines tested for human use against disease, COVID-19or otherwise, have generally required a double dose to be effective. And judging by poorcompliance with other multidose vaccines, many people who get the first shot probably won’t get the second.
New delivery systems could fix that. At Vaxess Technologies in Cambridge, Massachusetts, for example, researchers havedeveloped a wearable skin patch studded with tiny silk-tipped, dissolvable microneedles that slowly trickle vaccine into the body.
Administering the vaccine in drips instead of all at once could help to solve a third drawback: side effects. Severe reactions,although transient, do seem to be more common with COVID-19 shots than with other immunizations — more than 80% of peoplewho received the Moderna vaccine in clinical trials had some type of systemic reaction to the shot, with bouts of fatigue, musclepain and other issues that often proved briefly debilitating.
That unpleasantness might be acceptable in the midst of a deadly global pandemic, says vaccinologist Stanley Plotkin, whoconsults for many vaccine manufacturers. But people might baulk at routinely feeling so ill for, say, their annual flu shot. And forany vaccines geared toward infants, “one would certainly want to have something less reactogenic”.
7
Search for better COVIDvaccines confounded by existingrollouts
RELATED
8
Contaminants in vaccine synthesis and the LNP delivery system are thought to be two of the main sources of reactogenicity.Purification systems are only so good, and LNPs can be optimized only so much. For these reasons, vaccine manufacturers oftenadminister lower doses to limit a person’s exposure to both. With a conventional RNA vaccine, lower doses mean lower potency.But companies such as Arcturus Therapeutics in San Diego, California, and VaxEquity in London have devised workarounds bycreating self-amplifying RNA constructs for their COVID-19 vaccines (see ‘How RNAs can work harder’).
In small doses
Unlike the front-runner RNA-based vaccines, which contain little more than the coding sequence for the coronavirus spike proteinflanked by regulatory regions on either end, these self-replicating vaccine candidates also include instructions for the RNA tocopy itself.
The vaccine constructs are a bit clunkier, requiring more sequence optimization and manufacturing finesse. But they allowcompanies to lower the dose. And the replicating RNA more closely mimics a natural viral infection — triggering a stronger,broader immune response, which might allow for single-dose inoculation regimens.
Nik Spencer/
Nature
BioNTech has improved on the amplifying technology
. Before COVID-19, the company focused mostly on cancer vaccines. Butwith a proven reputation, expanded production capacity and substantial cash flow expected from sales of the COVID-19 vaccine,“that will allow us to expand on the infectious-disease platform much faster”, says BioNTech co-founder and chief executive UğurŞahin.
Ziphius Vaccines in Oostkamp, Belgium, has similarly tried to capitalize on coronavirus momentum. Founded in May 2019 —initially to develop RNA-based treatments for rare diseases such as Duchenne muscular dystrophy and cystic fibrosis — Ziphiusoverhauled its development plans last year after starting to work on a self-amplifying RNA vaccine for COVID-19. Chief executive
9
Chris Cardon says the start-up is now trying to raise €30 million (US$37 million) to advance 14 preclinical programmes for avariety of infectious diseases.
RNA vaccines might yet face financial headwinds. Many industry insiders don’t expect the current white-hot interest to last oncethe pandemic subsides.
“It’s pretty hard to talk people into taking bets on this type of technology for vaccines in infectious diseases,” says Nathaniel Wang,chief executive of Replicate Bioscience in San Diego, California, a company he co-founded last year with Geall to develop RNA-based treatments for cancer. And although Replicate has forged some academic and commercial partnerships around RNAvaccines for COVID-19 and Zika, it’s not what most venture-capital firms want to fund, says Wang.
Still, with RNA vaccines making headlines, Geall and many of his former colleagues have been replaying their days at Novartis. Hadthe company not sold off its vaccines unit, could they have helped to stamp out Ebola or Zika outbreaks in the past decade?
“There’s always a little bit of sadness looking back,” says Christian Mandl, former head of research and early clinical developmentat Novartis’s vaccines unit. But he takes solace in the success of the COVID-19 vaccines today. “I am very proud that we made avaluable contribution.”
Nature
589
, 189-191 (2021)
doi:
https://doi.org/10.1038/d41586-021-00019-w
Jobs from Nature Careers ›
All jobs
References
Geall, A. J.
et al.
Proc. Natl Acad. Sci. USA
109
, 14604–14609 (2012).
1.
Hekele, A.
et al.
Emerg. Microbes Infect.
2
, e52 (2013).
2.
Ulmer, J. B., Mansoura, M. K. & Geall, A. J.
Expert Opin. Drug Discov.
10
, 101–106 (2015).
3.
MartinonF
etal
EurJImmunol
23
1719–1722(1993)
4
show more
Research Technician I
Baylor College of Medicine (BCM)
Houston, TX, United States
JOB POST
Tenure track Assistant Professor Positions in the Department of Psychology
Ashoka University
Nature
ISSN
1476-4687
(online)
© 2021 Springer Nature Limited
Sonepat, India
JOB POST
Group Leader (f/m/d) in Chemical Biology
University of Würzburg
Würzburg, Germany
JOB POST
Doctoral Researchers: 13 Fully Funded Positions in Data Science & Health
German Cancer Research Center in the Helmholtz Association (DKFZ)
Heidelberg, Karlsruhe, Germany
JOB POST
Are you busy and do not have time to handle your assignment? Are you scared that your paper will not make the grade? Do you have responsibilities that may hinder you from turning in your assignment on time? Are you tired and can barely handle your assignment? Are your grades inconsistent?
Whichever your reason is, it is valid! You can get professional academic help from our service at affordable rates. We have a team of professional academic writers who can handle all your assignments.
Students barely have time to read. We got you! Have your literature essay or book review written without having the hassle of reading the book. You can get your literature paper custom-written for you by our literature specialists.
Do you struggle with finance? No need to torture yourself if finance is not your cup of tea. You can order your finance paper from our academic writing service and get 100% original work from competent finance experts.
Computer science is a tough subject. Fortunately, our computer science experts are up to the match. No need to stress and have sleepless nights. Our academic writers will tackle all your computer science assignments and deliver them on time. Let us handle all your python, java, ruby, JavaScript, php , C+ assignments!
While psychology may be an interesting subject, you may lack sufficient time to handle your assignments. Don’t despair; by using our academic writing service, you can be assured of perfect grades. Moreover, your grades will be consistent.
Engineering is quite a demanding subject. Students face a lot of pressure and barely have enough time to do what they love to do. Our academic writing service got you covered! Our engineering specialists follow the paper instructions and ensure timely delivery of the paper.
In the nursing course, you may have difficulties with literature reviews, annotated bibliographies, critical essays, and other assignments. Our nursing assignment writers will offer you professional nursing paper help at low prices.
Truth be told, sociology papers can be quite exhausting. Our academic writing service relieves you of fatigue, pressure, and stress. You can relax and have peace of mind as our academic writers handle your sociology assignment.
We take pride in having some of the best business writers in the industry. Our business writers have a lot of experience in the field. They are reliable, and you can be assured of a high-grade paper. They are able to handle business papers of any subject, length, deadline, and difficulty!
We boast of having some of the most experienced statistics experts in the industry. Our statistics experts have diverse skills, expertise, and knowledge to handle any kind of assignment. They have access to all kinds of software to get your assignment done.
Writing a law essay may prove to be an insurmountable obstacle, especially when you need to know the peculiarities of the legislative framework. Take advantage of our top-notch law specialists and get superb grades and 100% satisfaction.
We have highlighted some of the most popular subjects we handle above. Those are just a tip of the iceberg. We deal in all academic disciplines since our writers are as diverse. They have been drawn from across all disciplines, and orders are assigned to those writers believed to be the best in the field. In a nutshell, there is no task we cannot handle; all you need to do is place your order with us. As long as your instructions are clear, just trust we shall deliver irrespective of the discipline.
Our essay writers are graduates with bachelor's, masters, Ph.D., and doctorate degrees in various subjects. The minimum requirement to be an essay writer with our essay writing service is to have a college degree. All our academic writers have a minimum of two years of academic writing. We have a stringent recruitment process to ensure that we get only the most competent essay writers in the industry. We also ensure that the writers are handsomely compensated for their value. The majority of our writers are native English speakers. As such, the fluency of language and grammar is impeccable.
There is a very low likelihood that you won’t like the paper.
Not at all. All papers are written from scratch. There is no way your tutor or instructor will realize that you did not write the paper yourself. In fact, we recommend using our assignment help services for consistent results.
We check all papers for plagiarism before we submit them. We use powerful plagiarism checking software such as SafeAssign, LopesWrite, and Turnitin. We also upload the plagiarism report so that you can review it. We understand that plagiarism is academic suicide. We would not take the risk of submitting plagiarized work and jeopardize your academic journey. Furthermore, we do not sell or use prewritten papers, and each paper is written from scratch.
You determine when you get the paper by setting the deadline when placing the order. All papers are delivered within the deadline. We are well aware that we operate in a time-sensitive industry. As such, we have laid out strategies to ensure that the client receives the paper on time and they never miss the deadline. We understand that papers that are submitted late have some points deducted. We do not want you to miss any points due to late submission. We work on beating deadlines by huge margins in order to ensure that you have ample time to review the paper before you submit it.
We have a privacy and confidentiality policy that guides our work. We NEVER share any customer information with third parties. Noone will ever know that you used our assignment help services. It’s only between you and us. We are bound by our policies to protect the customer’s identity and information. All your information, such as your names, phone number, email, order information, and so on, are protected. We have robust security systems that ensure that your data is protected. Hacking our systems is close to impossible, and it has never happened.
You fill all the paper instructions in the order form. Make sure you include all the helpful materials so that our academic writers can deliver the perfect paper. It will also help to eliminate unnecessary revisions.
Proceed to pay for the paper so that it can be assigned to one of our expert academic writers. The paper subject is matched with the writer’s area of specialization.
You communicate with the writer and know about the progress of the paper. The client can ask the writer for drafts of the paper. The client can upload extra material and include additional instructions from the lecturer. Receive a paper.
The paper is sent to your email and uploaded to your personal account. You also get a plagiarism report attached to your paper.
GET A PERFECT SCORE!!! 
Delivering a high-quality product at a reasonable price is not enough anymore.
That’s why we have developed 5 beneficial guarantees that will make your experience with our service enjoyable, easy, and safe.
You have to be 100% sure of the quality of your product to give a money-back guarantee. This describes us perfectly. Make sure that this guarantee is totally transparent.
Read moreEach paper is composed from scratch, according to your instructions. It is then checked by our plagiarism-detection software. There is no gap where plagiarism could squeeze in.
Read moreThanks to our free revisions, there is no way for you to be unsatisfied. We will work on your paper until you are completely happy with the result.
Read moreYour email is safe, as we store it according to international data protection rules. Your bank details are secure, as we use only reliable payment systems.
Read moreBy sending us your money, you buy the service we provide. Check out our terms and conditions if you prefer business talks to be laid out in official language.
Read more